By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting originating in Groningen, Netherlands, by NewsRx journalists, research stated, "The efficacy of anidulafungin is driven by the area under the concentration-time curve (AUC)/MIC ratio. Patients in intensive care may be at risk for underexposure."
The news reporters obtained a quote from the research from the University of Groningen, "In critically ill patients with an invasive Candida infection, the anidulafungin exposure and a possible correlation with disease severity or plasma protein levels were explored. Concentration-time curves were therefore obtained at steady state. Anidulafungin concentrations were measured with a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The MIC values of the Candida species were determined with the Etest. The target AUC/MIC ratio was based on European Committee on Antimicrobial Susceptibility Testing (EUCAST) data. Twenty patients were included. The patients received a maintenance dose of 100 mg once daily after a loading dose of 200 mg on the first day. The mean (+/- standard deviation) AUC, maximum concentration of drug in plasma (C-max), and minimum concentration of drug in plasma (C-min) were 69.8 +/- 24.1 mg. h/liter, 4.7 +/- 1.4 mg/liter, and 2.2 +/- 0.8 mg/liter, respectively. The MIC values of all cultured Candida species were below the EUCAST MIC breakpoints. The exposure to anidulafungin in relation to the MIC that was determined appeared sufficient in all patients. The anidulafungin exposure was low in our critically ill patients. However, combined with the low MICs of the isolated Candida strains, the lower exposure observed in comparison to the exposure in the general patient population resulted in favorable AUC/MIC ratios, based on EUCAST data. No correlation was observed between anidulafungin exposure and disease severity or plasma protein concentrations."
According to the news reporters, the research concluded: "In patients with less-susceptible Candida albicans or glabrata strains, we recommend considering determining the anidulafungin exposure to ensure adequate exposure."
For more information on this research see: Low but Sufficient Anidulafungin Exposure in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2014;58(1):304-308. Antimicrobial Agents and Chemotherapy can be contacted at: Amer Soc Microbiology, 1752 N St NW, Washington, DC 20036-2904, USA. (American Society for Microbiology - www.asm.org; Antimicrobial Agents and Chemotherapy - aac.asm.org)
Our news correspondents report that additional information may be obtained by contacting M.J.P. van Wanrooy, University of Groningen, Dept. of Pharm, Pharmacotherapy & Pharmaceut Care Div, Groningen, Netherlands. Additional authors for this research include M.G.G. Rodgers, D.R.A. Uges, J.P. Arends, J.G. Zijlstra, T.S. van der Werf, J.G.W. Kosterink and J.W.C. Alffenaar (see also Drugs and Therapies).
Keywords for this news article include: Antibiotics, Antifungals, Antiinfectives, Europe, Groningen, Netherlands, Anidulafungin, Echinocandins, Drugs and Therapies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC